Industry snapshot: MedTech confronting tariff headwinds amidst tepid growth

Leading MedTech companies reported modest growth and more than $2 billion in cumulative anticipated tariff impact on earnings late 2025. Here is how QA/RA professionals can support their businesses.

Leading MedTech companies continue to face a challenging business environment in 2025. Our industry is reasonably accustomed to handling pressure from rapidly changing technology, intense competition, regulatory uncertainty and pricing pressures. Now, there is an emerging threat on the horizon.

Tariffs - and uncertainty around their implementation - are going to add to the already intense pressure on the bottom line.

Top 10 leading MedTech companies anticipate over $2 billion in cumulative tariff impact on earnings in the second half of 2025 and early 2026. This despite the fact that steepest tariffs announced, especially on imports from China, are currently on a 90-day pause.

They are rushing to implement a variety of mitigating measures likely to take away scarce resources away from product innovations that fuel topline growth and profitability.

In this article, we review the most recent business results, estimated tariff impact, mitigation strategies, and how QA/RA and Medical professionals can contribute to these efforts.